Evidence map›Paper›PMID 40794772›Full record

ArticleGenetics2025

Targeted loss of heterozygosity in Candida albicans using CRISPR-Cas9 reveals the functional impact of allelic variation.

Philippe C Després, Nicholas C Gervais, Meea Fogal, Ruby K J Rogers, Christina A Cuomo, Rebecca S Shapiro

Abstract read
In one paragraph

Article in Genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Philippe C DesprésInfectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA 02142, United States.ORCID 0000-0003-1407-0643
Nicholas C GervaisDepartment of Molecular and Cellular Biology, University of Guelph, Guelph, ON N1G 2W1, Canada.ORCID 0000-0002-9971-0031
Meea FogalDepartment of Molecular and Cellular Biology, University of Guelph, Guelph, ON N1G 2W1, Canada.ORCID 0000-0002-0483-9626
Ruby K J RogersDepartment of Molecular and Cellular Biology, University of Guelph, Guelph, ON N1G 2W1, Canada.
Christina A CuomoInfectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA 02142, United States.ORCID 0000-0002-5778-960X
Rebecca S ShapiroDepartment of Molecular and Cellular Biology, University of Guelph, Guelph, ON N1G 2W1, Canada.ORCID 0000-0002-7119-8865

Funding

Viral Genomics: evolution, spread, and host interactionsU19AI110818 · NIAID · BROAD INSTITUTE, INC. · PI EARL, ASHLEE MIRIAM · 2014 to 2024
$66.5M
C.A.C.Canada Research ChairCIFARCIHR PJT 162195FRQSFungal KingdomM.F.N.C.G.NIAID NIH HHS U19 AI110818NSERCR.S.S.
6 · The paper itself

Abstract

The diploid genome of the fungal pathogen Candida albicans is highly heterozygous, with most allele pairs diverging at either the coding or regulatory level. When faced with selection pressure like antifungal exposure, this hidden genetic diversity can provide a reservoir of adaptive mutations through loss of heterozygosity (LOH) events. Validating the potential phenotypic impact of LOH events observed in clinical or experimentally evolved strains can be difficult due to the challenge of precisely targeting one allele over the other. Here, we show that a CRISPR-Cas9 system can be used to overcome this challenge. By designing allele-specific guide RNA sequences, we can induce targeted, directed LOH events, which we validate by whole-genome long-read sequencing. Using this approach, we efficiently recapitulate a recently described LOH event that increases resistance to the antifungal fluconazole. Additionally, we find that the recombination tracts of these induced LOH events have similar lengths to those observed naturally. To facilitate future use of this method, we provide a database of allele-specific sgRNA sequences for Cas9 that provide near genome-wide coverage of heterozygous sites through either direct or indirect targeting. This approach will be useful in probing the adaptive role of LOH events in this important human pathogen.

Indexed as

Candida albicansCRISPR-Cas SystemsLoss of HeterozygosityAllelesAntifungal AgentsDrug Resistance, FungalGene EditingGenetic VariationGenome, FungalRNA, Guide, CRISPR-Cas SystemsAntifungal AgentsRNA, Guide, CRISPR-Cas Systemsantifungal resistanceCandida albicansCRISPR-Cas9fungal geneticsgenome editingLOH

Identifiers

PMID40794772
PMCPMC12505295

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.